JAZZ

JAZZ

USD

Jazz Pharmaceuticals plc Common Stock (Ireland)

$110.800+2.280 (2.101%)

Real-time Price

Healthcare
Biotechnology
Ireland

Price Chart

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$108.520

High

$111.170

Low

$107.660

Volume

0.01M

Company Fundamentals

Market Cap

6.7B

Industry

Biotechnology

Country

Ireland

Trading Stats

Avg Volume

1.16M

Exchange

NMS

Currency

USD

52-Week Range

Low $95.49Current $110.800High $148.06

Related News

PR Newswire

Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

View more
Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
PR Newswire

Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present seven abstracts at the American...

View more
Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma
PR Newswire

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025, after...

View more
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
PR Newswire

Jazz Pharmaceuticals Completes Acquisition of Chimerix

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of Chimerix, Inc....

View more
Jazz Pharmaceuticals Completes Acquisition of Chimerix
Analyst Upgrades

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $210 Price Target

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals with a Buy and maintains $210 price target.

View more
Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $210 Price Target